ArriVent Names Successor for Research and Development Leadership

Company ArriVent BioPharma Event Type Executive retirement and succession Modality EGFR inhibitor; antibody-drug conjugates Asset Firmonertinib; ARR-217; ARR-002 Target EGFR; CDH17; MUC16 and NaPi2b Disease Area Non-small-cell lung cancer; GI and gynecologic oncology Summary ArriVent co-founder Stuart Lutzker will retire as president of R&D and…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *